To protect managed care pharmacy practices that help patients get the medications they need at a cost they can afford, AMCP submits amicus brief in Rutledge v. The Pharmaceutical Care Management Association (PCMA).
This JMCP article analyzes the cost-effectiveness of brexanolone compared to SSRIs for postpartum depression. Findings indicate that brexanolone may serve as a cost-effective option over SSRIs.
The Partnership to Amend 42 CFR Part 2, a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), today issued the following statement in response to the bipartisan passage of the Coronavirus Aid, Relief, and Economic Security Act.
The Partnership to Amend 42 CFR Part 2 (Partnership), a coalition of nearly 50 health care organizations committed to aligning 42 CFR Part 2 (Part 2) with the Health Insurance Portability and Accountability Act (HIPAA) for the purposes of treatment, payment, and health care operations (TPO), thanks Senators Capito and Manchin, along with all the other champions and co-sponsors of the Legacy Act for their tireless work and dedication to combatting the opioid epidemic.
We, as patients, consumers, taxpayers, health care providers, payers, and members of the pharmaceutical and medical device pipeline, are ready to work with The President's Administration to ensure that America’s patients and our health care system receive the treatments they need throughout this public health crisis.
These are trying times, especially for health care practitioners. Together, as managed care pharmacy professionals, we face challenges to patient care. AMCP CEO Susan A. Cantrell, RPh, CAE addresses these unique challenges in her latest blog post.